<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244010</url>
  </required_header>
  <id_info>
    <org_study_id>SAAHAP</org_study_id>
    <secondary_id>Severe Aplastic Anemia</secondary_id>
    <secondary_id>Cytopenias</secondary_id>
    <nct_id>NCT00244010</nct_id>
  </id_info>
  <brief_title>Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation (HSCT) From Partially Matched Family Donors for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to an overall and disease free survival of 85% to 100%, allogeneic blood or bone marrow
      stem cell transplantation using an HLA matched sibling donor is the therapy of choice for
      patients with severe aplastic anemia (SAA). Unfortunately, only about 25% of patients have
      such a donor. For patients with SAA lacking a matched sibling donor, immunosuppressive
      therapy is the current treatment of choice. Approximately 70% of these patients have a
      complete or partial response to immunosuppressive therapy, achieving transfusion independence
      and/or growth factor independence.

      For the approximately 30% of patients who do not respond to immunosuppressive therapy or
      experience recurrence, alternative donor (matched unrelated, partially matched family member)
      transplantation is a treatment option. However, graft rejection and graft-versus-host-disease
      (GVHD) are significant barriers to success, decreasing event-free survival to 30% to 50%.

      This study offers stem cell transplantation using a partially matched family member
      (haploidentical) donor to those patients with no available HLA-matched sibling or matched
      unrelated donor. In an attempt to reduce GVHD and regimen-related toxicity while maintaining
      adequate engraftment, we plan to infuse a highly purified stem cell graft. The Miltenyi
      Biotec CliniMACS CD3 depletion system will be used to derive a defined allogeneic graft
      highly enriched for CD34+ hematopoietic cells and depleted of CD3+ T-lymphocytes from G-CSF
      mobilized, donor-derived peripheral blood stem cells.

      Patients 21 years of age and younger with refractory cytopenias are also eligible for this
      protocol as there are no other potentially curative therapies currently available for these
      conditions.

      The primary objective of this study is to evaluate the safety of transplantation using a
      haploidentical donor product engineered to targeted cell counts using the investigational
      CliniMACS device for patients with refractory severe aplastic anemia (SAA) or refractory
      cytopenias. The treatment plan would be considered unsafe if we can find this type of
      procedure is associated with a significantly higher treatment failure rate. Treatment failure
      is defined as any occurrence of the following events, overall grade III-IV acute GVHD, graft
      failure or death due to any cause within 100 days after transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives for this protocol include the following:

        -  To observe the degree of hematopoietic chimerism in T-cells during the first year
           posttransplant.

        -  To observe the relative proportions of donor/host T-regulatory cells during the first
           year posttransplant.

        -  To monitor rates of acute and chronic GVHD during the first year posttransplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failures</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>The primary objective of this study is to evaluate the safety of HAPLO HSCT for patients with refractory severe aplastic anemia (SAA) or refractory cytopenias. The treatment plan would be considered unsafe if we can demonstrate that it is associated with a significantly higher treatment failure rate. The treatment failure is defined as any occurrence of the following events, overall grade III-IV acute GVHD, graft failure or death due to any cause within 100 days post HSCT or after the last cellular product infusion, if required.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Anemia, Aplastic</condition>
  <condition>Amegakaryocytic Thrombocytopenia</condition>
  <condition>Diamond-Blackfan Anemia</condition>
  <condition>Kostmann Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Allogeneic stem cell transplant</intervention_name>
    <description>Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Allogeneic stem cell transplantation</other_name>
    <other_name>Haploidentical stem cell transplant</other_name>
    <other_name>T-cell depletion</other_name>
    <other_name>Partially matched family member donor transplant</other_name>
    <other_name>Hematopoietic stem cell transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One of the following diagnoses:

          -  Refractory severe aplastic anemia

          -  Refractory Kostmann syndrome

          -  Refractory Diamond-Blackfan anemia

          -  Refractory amegakaryocytic thrombocytopenia

          -  Absence of a suitable HLA-matched sibling donor and absence of a 10/10 allele matched
             unrelated donor.

          -  Life expectancy of greater than six weeks as per the judgment of the principal
             investigator.

          -  Karnofsky or Lansky Performance Status score of greater than or equal to 70%.

          -  Creatinine clearance is greater than or equal to 40 cc/min/1.73 m2.

          -  FVC greater than or equal to 40% of predicted or pulse oximetry greater than or equal
             to 92% on room air.

          -  Does not have a known allergy to murine products.

        Exclusion criteria:

          -  Ejection fraction or shortening fraction below the lower limit of normal for age.

          -  Lactating (female patient).

          -  Pregnant or lactating

          -  Diagnosis of Fanconi Anemia.

          -  Positive HLA crossmatch with donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Kasow, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2005</study_first_submitted>
  <study_first_submitted_qc>October 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2005</study_first_posted>
  <results_first_submitted>February 2, 2012</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aplastic anemia</keyword>
  <keyword>Amegakaryocytic thrombocytopenia</keyword>
  <keyword>Diamond-Blackfan Anemia</keyword>
  <keyword>Kostmann syndrome</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>Haploidentical stem cell transplant</keyword>
  <keyword>T-cell depletion</keyword>
  <keyword>Partially matched family member donor transplant</keyword>
  <keyword>Refractory cytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two patients and two donors were enrolled between 10/24/2005 and 2/24/2009 when the study was closed. The study was terminated due to the PI leaving St. Jude.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients</title>
          <description>Patients were enrolled to treat refractory severe aplastic anemia.</description>
        </group>
        <group group_id="P2">
          <title>Donors</title>
          <description>Parents of patients were enrolled onto the SAAHAP study to provide hematopoietic stem cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients</title>
          <description>Patients were enrolled to treat refractory severe aplastic anemia.</description>
        </group>
        <group group_id="B2">
          <title>Donors</title>
          <description>Parents of patients were enrolled onto the SAAHAP study to provide hematopoietic stem cells.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failures</title>
        <description>The primary objective of this study is to evaluate the safety of HAPLO HSCT for patients with refractory severe aplastic anemia (SAA) or refractory cytopenias. The treatment plan would be considered unsafe if we can demonstrate that it is associated with a significantly higher treatment failure rate. The treatment failure is defined as any occurrence of the following events, overall grade III-IV acute GVHD, graft failure or death due to any cause within 100 days post HSCT or after the last cellular product infusion, if required.</description>
        <time_frame>100 days post transplant</time_frame>
        <population>Enrollment was terminated due to the PI leaving the institution. Insufficient data was generated to answer the objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Patients were enrolled to treat refractory severe aplastic anemia.</description>
          </group>
          <group group_id="O2">
            <title>Donors</title>
            <description>Parents of patients were enrolled onto the SAAHAP study to provide hematopoietic stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failures</title>
          <description>The primary objective of this study is to evaluate the safety of HAPLO HSCT for patients with refractory severe aplastic anemia (SAA) or refractory cytopenias. The treatment plan would be considered unsafe if we can demonstrate that it is associated with a significantly higher treatment failure rate. The treatment failure is defined as any occurrence of the following events, overall grade III-IV acute GVHD, graft failure or death due to any cause within 100 days post HSCT or after the last cellular product infusion, if required.</description>
          <population>Enrollment was terminated due to the PI leaving the institution. Insufficient data was generated to answer the objective.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two patients and two donors were enrolled between 10/24/2005 and 2/24/2009 when the study was closed.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients</title>
          <description>Patients were enrolled to treat refractory severe aplastic anemia.</description>
        </group>
        <group group_id="E2">
          <title>Donor</title>
          <description>Donors were not assessed for adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal Pain (intermittent)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Infection, Staphylococcus Aureus, Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting (intermittent)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever without Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly (intermittent)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Ferritin Level</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hemosiderosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Iron overload (intermittent)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain-Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study has terminated due to the PI leaving the institution. An insufficient number of subjects were enrolled to answer the primary objective.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kimberly Kasow, DO</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>901-595-3300</phone>
      <email>kimberly_kasow@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

